^
Association details:
| Biomarker: | ANXA1 overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | MDX-124 (Annexin A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1874 - MDX-124, a novel annexin-A1 antibody, induces an anti-tumor immune response and wide-ranging anti-cancer activity in multiple preclinical models
Published date:
03/10/2021
Excerpt:
ANXA1 expression in the subcellular compartments (nucleus, cytoplasm and membrane) was quantified in a panel of cancer cell lines via imaging flow cytometry and the anti-proliferative effect of MDX-124 was shown to correlate with membrane ANXA1 expression...TNBC and acute myeloid leukemia cell lines exposed to MDX-124 exhibited a statistically significant reduction in migration compared to untreated controls....our data indicate that...MDX-124 inhibits tumorigenic processes and induces an immune response in tumors overexpressing ANXA1.
